EA202290027A1 - METHODS AND COMPOSITIONS FOR IMPROVING TREATMENT OUTCOMES IN CANCER PATIENTS - Google Patents

METHODS AND COMPOSITIONS FOR IMPROVING TREATMENT OUTCOMES IN CANCER PATIENTS

Info

Publication number
EA202290027A1
EA202290027A1 EA202290027A EA202290027A EA202290027A1 EA 202290027 A1 EA202290027 A1 EA 202290027A1 EA 202290027 A EA202290027 A EA 202290027A EA 202290027 A EA202290027 A EA 202290027A EA 202290027 A1 EA202290027 A1 EA 202290027A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical grade
buffer
compositions
methods
cancer patients
Prior art date
Application number
EA202290027A
Other languages
Russian (ru)
Inventor
Джеймс Эрвин
Хендрик Йоханнес Петрюс Ван Вик
Брайан Дэвид Деномм
Мариетт Луиз Ван Вик
Питер Пакульт
Майкл А. Волк
Натали Мария Пиццименти
Питер Б. Ланге
Original Assignee
РИВЕН АйПи ХОЛДКО ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by РИВЕН АйПи ХОЛДКО ЭлЭлСи filed Critical РИВЕН АйПи ХОЛДКО ЭлЭлСи
Publication of EA202290027A1 publication Critical patent/EA202290027A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Изобретение относится к композициям и способам для улучшения результатов лечения пациентов с раком. В частности, к способу предотвращения, облегчения или лечения рака, включающему введение субъекту, который нуждается в этом, эффективного количества композиции, где композиция содержит по меньшей мере одну кислоту фармацевтической категории и по меньшей мере одно регулирующее pH буферное средство фармацевтической категории в стерильном водном растворе, где концентрация кислоты фармацевтической категории и регулирующего pH буферного средства фармацевтической категории в буферном растворе является достаточной для обеспечения общего содержания титруемой кислоты от 60 до 3000 ммоль/л при введении субъекту и где выбор кислоты фармацевтической категории и регулирующего pH буферного средства фармацевтической категории является эффективным для обеспечения значения pH буферного раствора, составляющего от 4,0 до 7,7.The invention relates to compositions and methods for improving the results of treatment of patients with cancer. In particular, a method of preventing, alleviating, or treating cancer comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises at least one pharmaceutical grade acid and at least one pharmaceutical grade pH adjusting buffer in a sterile aqueous solution. where the concentration of pharmaceutical grade acid and pharmaceutical grade pH buffer in the buffer solution is sufficient to provide a total titratable acid of 60 to 3000 mmol/L when administered to a subject, and where the choice of pharmaceutical grade acid and pharmaceutical grade pH buffer is effective for ensuring the pH value of the buffer solution is from 4.0 to 7.7.

EA202290027A 2019-06-12 2020-06-12 METHODS AND COMPOSITIONS FOR IMPROVING TREATMENT OUTCOMES IN CANCER PATIENTS EA202290027A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962860642P 2019-06-12 2019-06-12
PCT/US2020/037398 WO2020252238A1 (en) 2019-06-12 2020-06-12 Methods and compositions for improving outcomes of cancer patients

Publications (1)

Publication Number Publication Date
EA202290027A1 true EA202290027A1 (en) 2022-03-29

Family

ID=73745688

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202290027A EA202290027A1 (en) 2019-06-12 2020-06-12 METHODS AND COMPOSITIONS FOR IMPROVING TREATMENT OUTCOMES IN CANCER PATIENTS

Country Status (14)

Country Link
US (1) US20200390743A1 (en)
EP (1) EP3982947A1 (en)
JP (1) JP2022536708A (en)
KR (1) KR20220029657A (en)
CN (1) CN114222566A (en)
AR (1) AR120059A1 (en)
AU (1) AU2020293232A1 (en)
BR (1) BR112021025105A2 (en)
CA (1) CA3141418A1 (en)
EA (1) EA202290027A1 (en)
IL (1) IL288787A (en)
MX (1) MX2021015228A (en)
TW (1) TW202112358A (en)
WO (1) WO2020252238A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents
US20230135127A1 (en) * 2021-10-28 2023-05-04 Wei-ping Zeng Compositions and methods for disease treatment and prevention by ph modifiers and/or cell proliferation inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135948A (en) * 1988-11-21 1992-08-04 Norsk Hydro A.S. Pharmaceutical compositions with anti-cancer activity against carcinoma and method for the treatment of carcinoma
AU5871000A (en) * 1999-06-11 2001-01-02 Paul G. Abrams High dose radionuclide complexes for bone marrow suppression
US20040110684A1 (en) * 1999-08-02 2004-06-10 Universite Catholique De Louvain Novel pharmaceutical compositions for modulating angiogenesis
WO2005044176A2 (en) * 2003-11-10 2005-05-19 Lipogen Ltd. Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same
CU23432B6 (en) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech STABILIZED FORMULATIONS CONTAINING GAMMA AND ALFA INTERFERONS IN POTENTIAL PROPORTIONS
EP2109608B1 (en) * 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
CN104997803B (en) * 2010-07-22 2019-07-09 雷文制药有限公司 Comprising the treatment using magnetic dipole stabilizing solutions or improves disease and enhance the method and composition of performance
RU2693487C2 (en) * 2013-08-07 2019-07-03 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Peptides capable of reactivating p53 mutants

Also Published As

Publication number Publication date
IL288787A (en) 2022-02-01
CA3141418A1 (en) 2020-12-17
KR20220029657A (en) 2022-03-08
WO2020252238A1 (en) 2020-12-17
MX2021015228A (en) 2022-02-10
AU2020293232A1 (en) 2022-02-03
CN114222566A (en) 2022-03-22
JP2022536708A (en) 2022-08-18
US20200390743A1 (en) 2020-12-17
AR120059A1 (en) 2022-02-02
BR112021025105A2 (en) 2022-03-15
TW202112358A (en) 2021-04-01
EP3982947A1 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2019012113A (en) Gene therapy for aadc deficiency.
MX2011007854A (en) Methods for treating acute myocardial infarctions and associated disorders.
EA201491460A1 (en) APPLICATION OF LACHINIMODA IN THE TREATMENT OF PATIENTS WITH CRONE'S DISEASE, WHICH ARE NOT EFFECTIVE THERAPY OF THE FIRST LINE ANTI-TNFα
EA202290027A1 (en) METHODS AND COMPOSITIONS FOR IMPROVING TREATMENT OUTCOMES IN CANCER PATIENTS
HRP20080146T3 (en) Preoperative treatment of post operative pain
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
MX2020001768A (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel.
EA202191947A1 (en) METHODS FOR TREATING PAIN WITH THIAZOLINE ANTIHYPERALGESIC DRUG
MX2020002206A (en) Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash).
MX2020007817A (en) Sleep disorder treatment and prevention.
PH12020550066A1 (en) METHOD FOR TREATING TNFa-RELATED DISEASE
RU2537031C2 (en) Method of treating cystitis
BR112022001814A2 (en) Multifocal cancer treatment methods
EA202000298A1 (en) ANTICORONAVIRUS AGENT FOR COMBINATION THERAPY OF COVID-19 (SARS-CoV-2) AND METHOD OF TREATMENT
BR112021024835A2 (en) Treatment for synuclenopathies
MX2021015796A (en) Compositions and methods for treating eye diseases.
AU2024202170A1 (en) Use of an anti-P-selectin antibody
EA202090614A1 (en) METHODS FOR TREATING NON-ALCOHOLIC STEATHEPATITIS (NASH) USING THE MODIFIED FIBROBLAST 21 GROWTH FACTOR (FGF-21)
WO2017011762A1 (en) Treating rotator cuff conditions
TW202417044A (en) Pharmaceutical composition of anti-cd20 antibody and use thereof
MX2022016174A (en) Compositions and methods for treating obsessive-compulsive disorder.
MX2022002947A (en) Avocatin b for the treatment of diseases and conditions.
RU2417091C2 (en) Method of treating osteoarthritis